Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
CD93 maintains endothelial barrier function and limits metastatic dissemination
Kalyani Vemuri, Beatriz de Alves Pereira, Patricia Fuenzalida, Yelin Subashi, Stefano Barbera, Luuk van Hooren, Marie Hedlund, Fredrik Pontén, Cecilia Lindskog, Anna-Karin Olsson, Roberta Lugano, Anna Dimberg
Kalyani Vemuri, Beatriz de Alves Pereira, Patricia Fuenzalida, Yelin Subashi, Stefano Barbera, Luuk van Hooren, Marie Hedlund, Fredrik Pontén, Cecilia Lindskog, Anna-Karin Olsson, Roberta Lugano, Anna Dimberg
View: Text | PDF
Research Article Oncology Vascular biology

CD93 maintains endothelial barrier function and limits metastatic dissemination

  • Text
  • PDF
Abstract

Compromised vascular integrity facilitates extravasation of cancer cells and promotes metastatic dissemination. CD93 has emerged as a target for antiangiogenic therapy, but its importance for vascular integrity in metastatic cancers has not been evaluated. Here, we demonstrate that CD93 participates in maintaining the endothelial barrier and reducing metastatic dissemination. Primary melanoma growth was hampered in CD93–/– mice, but metastatic dissemination was increased and associated with disruption of adherens and tight junctions in tumor endothelial cells and elevated expression of matrix metalloprotease 9 at the metastatic site. CD93 directly interacted with vascular endothelial growth factor receptor 2 (VEGFR2) and its absence led to VEGF-induced hyperphosphorylation of VEGFR2 in endothelial cells. Antagonistic anti-VEGFR2 antibody therapy rescued endothelial barrier function and reduced the metastatic burden in CD93–/– mice to wild-type levels. These findings reveal a key role of CD93 in maintaining vascular integrity, which has implications for pathological angiogenesis and endothelial barrier function in metastatic cancer.

Authors

Kalyani Vemuri, Beatriz de Alves Pereira, Patricia Fuenzalida, Yelin Subashi, Stefano Barbera, Luuk van Hooren, Marie Hedlund, Fredrik Pontén, Cecilia Lindskog, Anna-Karin Olsson, Roberta Lugano, Anna Dimberg

×

Figure 5

CD93 knockdown impairs endothelial junctions in murine lung endothelial cells and promotes vascular permeability and tumor cell extravasation in lungs.

Options: View larger image (or click on image) Download as PowerPoint
CD93 knockdown impairs endothelial junctions in murine lung endothelial ...
(A) Western blot for CD93 and β-actin indicating the silencing efficiency of CD93 siRNAs in the mouse lung endothelial cells (mLECs). Values shown in the graph represent mean ± SEM (3 independent experiments). *P < 0.05 by 1-way ANOVA with Dunnett’s multiple-comparison test. Immunofluorescent staining of VE-cadherin (green) (B), claudin5 (green) (C), and ZO1 (green) (D) in control (Mock and siCtrl) and CD93 siRNA–silenced (siCD93-4 and siCD93-5) mLECs. Scale bars: 20 μm. Arrowheads point toward the disrupted endothelial junctions. Nuclei are visualized by Hoechst staining (blue). Representative images of dextran leakage in healthy (E) and in premetastatic lungs (G) in wild-type and CD93–/– mice. Scale bars: 20 μm. (F and H) Quantification of dextran leakage in wild-type and CD93–/– mice (n = 4–6/group, 4 fields of view/sample). Nuclei are visualized by Hoechst (blue). *P < 0.05 by 2-tailed t test. (I and K) Percentage of mice that developed metastases after intravenous injection (i.v.) of HCmel12 cells (I) or B16F10 cells (K). (J and L) Percentage of lung tissue area covered by metastases after i.v. injection of HCmel12 (J) and B16F10 cells (L). *P < 0.05 by Mann-Whitney test. Values represent mean ± SEM.

Copyright © 2026 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts